CA-125 and D-dimer show potential applications in diagnosing and managing adenomyosis. As a traditional tumor marker, CA-125 may show a trend of increase in patients with adenomyosis, but its specificity is insufficient, because it may also increase in various gynecological diseases. As a measure of coagulation activity, D-dimer may be associated with inflammation and tissue changes related to adenomyosis. However, its specific mechanism of action and diagnostic efficacy still need to be further studied. Current studies are limited by the small sample size, insufficient standardization and lack of dynamic monitoring data, these factors limit the general applicability of the conclusions and practical value of the application. Therefore, it is particularly urgent to conduct large-scale, prospective studies to verify the effectiveness of these biomarkers and to explore their combined application in the diagnosis and management of adenomyosis. This will help to develop more accurate diagnosis and treatment plans and enhance the scientificity of clinical decision-making.
Smith J, Brown P, 2020, The Role of CA-125 in Diagnosing Adenomyosis: A Systematic Review. The Lancet, 395(10220): 1234–1242.
Johnson L, Wang H, et al., 2019, D-dimer as a Biomarker in Gynecological Conditions: A Clinical Study. American Journal of Obstetrics and Gynecology, 220(2): 234.e1–234.e7.
Chen Y, Liu S, Zhang P, et al., 2021, Evaluating Biomarkers for Adenomyosis: An Overview of Current Research. Human Reproduction Update, 2021, 27(3): 456–472.
Xie T, Chu B, 2020, Efficacy of Xiaojie Ann Capsule Combined with Trienone in Treatment with Adenomyosis Patients and Its Effect on Their Serum CA125, Proprost F-2a. Maternal and Child Health Care in China, 38(5): 320–327.
Liu S, Sun G, Wang F, et al., 2019, The Expression Levels and Clinical Significances of Hsp90a, CEA, and CA199 in Peripheral Blood of Patients with Gastric Cancer. Anhui Medical Journal, 37(5): 245–252.
Chen Y, 2019, Clinical Significance of Serum CA125 Determination in Patients with Adenomyosis and Uterine Fibroids. Practical Electronic Journal of Gynecologic Endocrinology, 29(4): 312–318.
Wang X, Zhao H, Chen X, 2021, Effect of High-Intensity Focused Ultrasound Combined with GnRH-a on Serum CA125, PGF2a, Adiponectin in Patients with Adenomyosis. Chinese Journal of Family Planning, 35(2): 87–94.
Li Y, 2017, Expression of IGF-1, DLL 4, and VEGF in Endometriosis and Their Significance. Chinese Journal of Obstetrics and Gynecology, 26(1): 23–29.
Liu Y, Xu L, Zhu W, 2019, Value of Transvaginal Color Doppler Ultrasound Combined with Glycoantigen 125 in Screening for Adenomyosis. Chinese Drug and Clinical, 34(2): 78–85.
Zou K, Zhu Q, Li Z, et al., 2023, Efficacy of Plus and Subtraction Combined with Low Dose Mifepristone in Patients with Adenomyosis Dysmenorrhea and Its Effect on Serum VEGF and CA125. The World Journal of Integrated Traditional Chinese and Western Medicine, 29(7): 487–495.
Xing Y, 2017, Differential Expression of Cell Cycle Factors Geminin, Cdt 1, P16 and Ki67 in Cervical Intraepithelial Neoplasia Tissues. Chinese Journal of Obstetrics and Gynecology, 25(4): 134–139.
Yang D, 2020, Value of Comprehensive Nursing Intervention in Hysterectomy for the Treatment of Uterine Fibroids and Adenomyosis. Oriental Medicated Food, 6: 193–202.
Hong L, Chen X, 2019, Efficacy of Ultrasound-Guided Radiofrequency Ablation for Adenomyosis and Its Effect on Serum CA125. Journal of Modern Integrated Traditional Chinese and Western Medicine, 28(9): 702–709.
Li X, 2016, Expression and Clinical Significance of P-selectin, MTA 1, and Paxillin in Abdominal Wall Endometriosis and Adenomyosis. Chinese Journal of Obstetrics and Gynecology, 24(6): 332–338.
Yang D, 2016, BCL 2-L12 Expression in Endometrial Cancer and Its Relation to the Clinicopathological Parameters. Chinese Journal of Obstetrics and Gynecology, 23(5): 287–292.
Ding Q, Lu H, Lu Y, et al., 2023, Expression and Clinical Significance of ER Stress-Related Factor Oxygen Modulator Protein 150 in Adenomyosis. Chinese-Foreign Medical Research, 30(8): 519–525.